Chester County News and Community Website
Baudax Bio (NASDAQ: BXRX), headquartered in Malvern, PA, is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once-daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information, visit www.baudaxbio.com.
MALVERN, PA — In a significant corporate update, Chester County-based biotechnology firm Baudax Bio, Inc. (NASDAQ: BXRX) this week announced plans to initiate the clinical development of its groundbreaking therapy, …
Baudax Bio Prepares for Pioneering Clinical Development of TI-168, Aiming to Improve Hemophilia A Treatment Read More
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX) announced that the U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to its lead clinical candidate TI-168 for the …
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors Read More MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a biotechnology company, announced that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be …
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference Read More MALVERN, PA — Baudax Bio, Inc. this week announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, …
Baudax Bio Rewards Common Stock Holders with Distribution of Series C Preferred Stock Read More MALVERN, PA — Baudax Bio, Inc. (Nasdaq: BXRX) recently announced that it has entered into definitive agreements for the purchase and sale of 2,006,544 shares of its common stock and …
Baudax Bio Announced $1.9M At-The-Market Registered Direct Offering Read More MALVERN, PA — Baudax Bio, Inc. (Nasdaq: BXRX) this week announced results for the three and six months ended June 30, 2023, and provided a business update.
Baudax Bio Delivers Q2 2023 Financial Results and Business Update Read More MALVERN, PA — Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company, announced the recent acquisition of TeraImmune, a privately held a biotechnology company focused on discovery and development of novel …
Baudax Bio Acquires TeraImmune, Inc. Read More MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX) recently announced that it has adjourned its Annual Meeting of Shareholders without any business being conducted, due to a lack of shareholder …
Baudax Bio Announces Date of Reconvened Annual Meeting Read More MALVERN, PA — Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company, announced additional results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective …
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000 Read More MALVERN, PA — Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company, recently reported financial results for the quarter ended March 31, 2023, and provided a business update.
Baudax Bio Reports First Quarter Financial Results, Provides Business Update Read More